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Abstract 
Background: Yes-associated protein (YAP) is a candidate oncogene in various human cancers, and recently, it 
has been reported that YAP expression and its activity was enhanced by ΔNp63. However, the role of YAP and 
ΔNp63 expression in carcinogenesis and progression of oral squamous cell carcinoma (OSCC) has been 
unknown. Therefore, we investigated how YAP and ΔNp63 influence carcinogenesis and progression of OSCC. 
Methods: We performed immunohistochemical analyses in whole tissue samples to investigate YAP and 
ΔNp63 expression in normal oral mucosa, epithelial hyperplasia, oral epithelial dysplasia (OED; low/high 
grade), carcinoma in situ (CIS), and OSCC. Furthermore, in OSCC, we analyzed clinical significance by using 
Kaplan-Meier survival analysis. 
Results: In normal oral mucosa and epithelial hyperplasia, YAP expression was primarily confined to the basal 
and parabasal layers, but YAP expression was elevated in OED, CIS, and OSCC. In OED, YAP and ΔNp63 
expression levels were markedly higher in high grade than in low grade. In OSCC groups, YAP and ΔNp63 
expression patterns tended to differ according to histopathological differentiation of OSCC. Furthermore, the 
YAP high expression group, which showed YAP staining in >50% positive cells with strong cytoplasmic staining 
or >10% positive cells with nuclear reactivity, showed a tendency to have a poor survival rate.  
Conclusion: YAP and ΔNp63 expression levels correlated with grade of oral OED. Additionally, YAP 
expression was associated with OSCC survival rate. Our results suggested that YAP and ΔNp63 expression 
might serve as predictive markers to distinguish OSCC development and progression. 
Key words: YAP, ΔNp63, oral epithelial dysplasia, carcinoma in situ, oral squamous cell carcinoma  
Introduction 
Oral squamous cell carcinoma (OSCC) 
represents 90% of oral cancers. Alterations in the 
11q22 amplicon are detected in 5–15% of OSCC [1]. 
The gene, Yes-associated protein (YAP), located in 
11q22, is specifically amplified in 4 of 23 OSCC [2-3]. 
YAP is a transcription factor in the Hippo signaling 
pathway and implicate in the regulation of 
development, metabolism, organ size, and 
tumorigenesis [4-6]. YAP has also been proposed as a 
candidate oncogene in hepatocellular carcinoma, 
non-small cell lung carcinoma, esophageal squamous 
cell carcinoma, ovarian cancer, and gastric cancer 
[7-10]. 
p63 is an important cancer-related binding 
partner of YAP. p63 controls YAP activity in head and 
neck squamous cell carcinoma [11]. The p63 gene is 
expressed as two isoforms: one that contains an 
N-terminal p53-homologous transactivation domain 
(TAp63) or one that lacks this domain (ΔNp63) 
[12-13]. ΔNp63 isoforms were initially described as 
simple dominant-negative proteins with the ability to 
inhibit TAp63 and p53 activity. Furthermore, elevated 
expression of ΔNp63 in esophageal squamous cell 
carcinoma and laryngeal squamous cell carcinoma 
was reported. Recently, ΔNp63 was shown to not only 
directly bind to the region of YAP promoter and 
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induce its expression but also enhance YAP activity in 
squamous cell carcinoma [14]. However, there are few 
studies that described the relationship between YAP 
and ΔNp63 in carcinogenesis and progression of 
OSCC of human tissue specimens. OSCC progresses 
from oral premalignant lesions to oral epithelial 
dysplasia (OED), turning into carcinoma in situ (CIS) 
and finally becoming invasive OSCC. Therefore, in 
this study, we focused on YAP and ΔNp63 expression 
in normal oral mucosa, epithelial hyperplasia, OED 
(low/high grade), CIS, and OSCC of human tissue 
specimens. 
Material and Methods 
Patients and Samples 
Patient samples were obtained from the oral 
pathology Department of Okayama University 
(Okayama, Japan) from August 2005 to January 2017. 
This study was approved by the Ethics Committee of 
Okayama University Graduate School of Medicine, 
Dentistry and Pharmaceutical Sciences (Approval 
number: 1608-018). A total of 270 cases were enrolled 
in the retrospective study, including 20 cases of 
normal oral mucosa, 20 cases of epithelial hyper-
plasia, 50 cases of low-grade OED, 50 cases of high- 
grade OED, 50 cases of CIS, and 80 cases of OSCC. 
Tissue samples from 270 patients were collected 
during clinical biopsy or excision. None of the 
patients received chemotherapy, radiotherapy or 
immunotherapy before sampling. All collected 
samples were histologically diagnosed by two patho-
logists and classified according to the World Health 
Organization criteria. Diagnostic WHO criteria of 
epithelial dysplasia include structural and cytological 
changes: the cut-off point between low-grade and 
high-grade dysplasia is four structural changes and 
five cytological changes. Based on the histologic 
categories of CIS, CIS cases were divided into two 
groups: differentiated type that marked atypical cells 
in the basal and parabasal layers while maintaining 
maturation and differentiation of the stratified 
squamous epithelium and basaloid type with atypia 
into the upper third of the epithelium. OSCC cases 
were divided into three groups: well-differentiated, 
moderately differentiated, and poorly differentiated. 
Tissue samples were fixed in 10% neutral formalde-
hyde and embedded in paraffin. Then, these samples 
were cut into 4-μm-thick sections for immunohisto-
chemical (IHC) analyses and hematoxylin-eosin 
staining. 
IHC Analysis 
Paraffin-embedded tissue sections were 
deparaffinized and hydrated using routine 
techniques. Then, sections were reacted with 0.3% 
hydrogen peroxide methanol at room temperature for 
30 min. Thereafter, sections were immersed in 0.01 M 
citrate buffer for antigen retrieval in a high-pressure 
cooker. Subsequent staining was performed using 
antibodies against YAP (1:100, R&D Systems, 
Minneapolis, MN, USA) and ΔNp63 (1:100, BioLogo, 
Kronshagen, Germany). For antibody detection, the 
Vectastain Elite ABC kit (Vector Laboratories, Inc., 
Burlingame, CA, USA) against YAP and Histofine, 
Simple Stain MAX-PO (MULTI) (Nichirei Bioscience, 
Tokyo, Japan) against ΔNp63 was used following the 
manufacturers’ instructions. Finally, tissue sections 
were stained in 1:10000 diaminobenzidine tetra-
hydrochloride solution for visualization. Appropriate 
negative control sections were used in parallel in each 
run. 
IHC Labeling Evaluation 
According to a previous study [15], the intensity 
of YAP staining in IHC analyses was scored as 
follows: 0, complete absence of staining or positive 
cells only located in the basal layer or parabasal layer 
of oral squamous epithelium; 1, weak cytoplasmic 
staining; 2, <50% positive cells with strong 
cytoplasmic staining and <10% positive cells with 
nuclear staining. Additionally, we scored sections as a 
“3” if YAP staining was observed in >50% positive 
cells with strong cytoplasmic staining (type C) or 
>10% positive cells with nuclear reactivity (type N). 
ΔNp63 expression was considered positive if nuclear 
staining was present, and ΔNp63 staining was 
recorded as the percentage of ΔNp63-positive cells. 
The sections were blindly examined under the light 
microscope, and independently evaluated 100 
cells/5HPF per sample and got dominant score by 
two pathologists. 
Statistical Analysis 
All statistical analyses were conducted using 
IBM SPSS Statistics 24 (IBM, Chicago, IL, USA). 
Student’s t-test with Bonferroni correction was used 
to analyze YAP and ΔNp63 expression levels in all 
samples. Kaplan-Meier survival analysis was used to 
analyze YAP and ΔNp63 expression levels in OSCC 
samples. The log-rank test was used to analyze the 
association between patient survival rate with YAP 
and ΔNp63 expression among different groups. 
P<0.05 was considered statistically significant. 
Results 
YAP and ΔNp63 expression in normal oral 
mucosa, epithelial hyperplasia, OED, and CIS 
Representative examples of YAP and ΔNp63 
expression in oral samples are shown in Fig 1. YAP 
and ΔNp63 expression were observed in all cases. In 
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normal oral mucosa and epithelial hyperplasia, YAP 
was weakly observed in the cell cytoplasm and nuclei 
of the basal and parabasal layers, and ΔNp63 was 
observed in the cell nuclei of the basal and parabasal 
layers. In low-grade OED, within the lower third of 
squamous epithelium, YAP expression was weakly 
distributed in mainly the cell cytoplasm, and ΔNp63 
expression was observed in cell nuclei. However, in 
high-grade OED and CIS, YAP and ΔNp63 expression 
was mainly distributed from the basal layer up to the 
surface of squamous epithelium. Strong YAP express-
ion was observed in the cytoplasm (type C) and nuclei 
(type N) of neoplastic cells. In high-grade OED, type 
C was seen in the differentiated type of CIS. Con-
versely, type N was seen in the basaloid type of CIS. 
YAP immunolabeling scores and percentage of 
ΔNp63-positive cells in all samples are displayed in 
Fig 2. There was no significant difference in YAP 
immunolabeling scores and percentage of 
ΔNp63-positive cells between normal oral mucosa 
and epithelial hyperplasia (P>0.05). YAP and ΔNp63 
expression in normal oral mucosa and epithelial 
hyperplasia was significantly lower than that in OED 
and CIS (P<0.05). Additionally, YAP and ΔNp63 
expression in low-grade OED was significantly lower 
than that in high-grade OED and CIS (P<0.05). 
However, there was no significant difference in YAP 
and ΔNp63 expression between high-grade OED and 
CIS (P>0.05). 
YAP immunolabeling scores are summarized in 
Fig 3. In normal oral mucosa and epithelial 
hyperplasia, no cases had scores of 2 or 3. In 
high-grade OED and CIS, no cases had a score of 0. 
Score 3 was noted in 2.0% (1/50) of low-grade OED, 
54.0% (27/50) of high-grade OED, and 68.0% (34/50) 
of CIS. Among cases with score 3, type C was noted in 
100.0% (1/1) of low-grade OED, 77.7% (21/27) of 
high-grade OED, and 70.5% (24/34) of CIS; type N 
was noted in no cases of low-grade OED, 22.2% (6/27) 
of high-grade OED, and 29.4% (10/34) of CIS. 
YAP and ΔNp63 expression in OSCC samples 
YAP and ΔNp63 expression was detected in all 
OSCC samples and tended to differ according to 
histopathological differentiation of OSCC (Fig 3). 
 In well-differentiated OSCC, YAP and ΔNp63 
expression were found in the tumor invasion front; 
YAP and ΔNp63 expression was observed in cell 
nuclei. Conversely, in poorly differentiated OSCC, 
YAP and ΔNp63 were expressed in nearly all 
malignant epithelial cells; YAP expression was 
strongly observed in cell nuclei or cytoplasm, and 
ΔNp63 expression was observed in cell nuclei. 
Moderately differentiated OSCC exhibited two 
patterns that tend to have maturation or less 
maturation of squamous epithelium. In the former, 
YAP and ΔNp63 expression patterns were similar to 
well-differentiated OSCC. In the latter, YAP and 
ΔNp63 expression patterns were similar to poorly 
differentiated OSCC.  
YAP immunolabeling scores and percentage of 
ΔNp63-positive cells in all samples are displayed in 
Fig 4. Both YAP immunolabeling scores and 
percentage of ΔNp63-positive cells in all samples 
were high, and there was no significant difference in 
YAP expression among the three OSCC groups 
(P>0.05). ΔNp63 expression in moderately and poorly 
differentiated OSCC was significantly higher than 
that in well-differentiated OSCC (P<0.05). As for YAP 
immunolabeling scores, no cases had a score of 0. 
Score 3 was noted in 16.6% (5/30) of well- 
differentiated OSCC, 46.6% (14/30) of moderately 
differentiated OSCC, and 40.0% (8/20) of poorly 
differentiated OSCC. For cases with a score of 3, type 
C was noted in 80.0% (4/5) of well-differentiated 
OSCC, 78.5% (11/14) of moderately differentiated 
OSCC, and 75.0% (6/8) of poorly differentiated 
OSCC. 
YAP and ΔNp63 expression and survival rate 
in OSCC.  
The clinical and pathological information of 
OSCC patients are arranged in Table 1. We evaluated 
the relationship between YAP expression and the 
survival rate of OSCC patients (Fig 5). OSCC patients 
were classified into two groups according to YAP 
expression: high (score 3; n=43) and low (scores 0–2; 
n=37). There was no significant difference in the 
survival rate between the YAP high and low 
expression groups. Additionally, based on YAP 
immunolabeling scores, OSCC patients were 
classified into two groups: scores 1 group vs. 3 group, 
and scores 2 group vs. 3 group. There was no 
significant difference in the survival rate between 
score 3 and score 2 groups (P>0.05), but the 
disease-free survival rate in score 3 group was 
significantly lower than that in score 1 group 
(P=0.047). These results suggest that YAP expression 
correlates with the survival rate. 
We next investigated the relationship between 
ΔNp63 expression and the survival rate of OSCC 
patients. The average percentage of ΔNp63-positive 
cells was 72.9%. OSCC patients were classified into 
two groups as follows: ΔNp63 high expression group 
(>72.9% ΔNp63-positive cells; n=60) and ΔNp63 low 
expression group (<72.9% ΔNp63-positive cells; 
n=20). No statistically significant difference was 
observed in the survival rate between these two 
groups (P>0.05). 
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Figure 1. Representative photomicrographs of hematoxylin-eosin (H&E) staining (A, D, G, J, M, P, and S) and immunohistochemical staining for YAP (B, E, H, K, N, Q, and T) and 
ΔNp63 (C, F, I, L, O, R, and U) in oral samples. Oral samples were normal oral mucosa (A–C), epithelial hyperplasia (D–F), low-grade OED (G–I), high-grade OED (J–O) and CIS 
(P–U). In normal oral mucosa and epithelial hyperplasia, YAP was weakly observed in the cell cytoplasm and nuclei of the basal and parabasal layers, and ΔNp63 was observed in 
the cell nuclei of the basal and parabasal layers (A–F). In low-grade OED, within the lower third of squamous epithelium, YAP expression was weakly distributed mainly in the cell 
cytoplasm, and ΔNp63 was observed in cell nuclei (G–I). In high-grade OED and CIS, YAP and ΔNp63 expression was mainly distributed up to the whole thickness of squamous 
epithelium (J–U). Strong YAP expression was observed in the cell cytoplasm (type C) or nuclei (type N) of neoplastic cells (K, N, Q, and T). Bars: 20 μm. 
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Table 1. Clinical features of cases of oral squamous cell 
carcinoma 
 
 
 
Discussion 
The present study focused on YAP and ΔNp63 
expression in normal oral mucosa, epithelial 
hyperplasia, OED (low/high grade), CIS, and OSCC 
of human tissue specimens. IHC analyses showed that 
YAP was mainly distributed in atypical cells of oral 
OED (low/high grade) and CIS. YAP and ΔNp63 
expression in normal oral mucosa and epithelial 
hyperplasia was significantly lower than that in oral 
OED and CIS (P<0.05). Additionally, YAP and ΔNp63 
expression in high-grade OED, CIS, and OSCC was 
high. Our findings are consistent with a previous 
report that compared human precancerous lesion and 
cervical cancer with normal cervical mucosa, and 
observed that YAP expression was elevated in 
precancerous lesion and cervical cancer [15]. 
Additionally, it was reported that ΔNp63 is associated 
with the severity of oral OED [12], and ΔNp63 
enhances YAP activity in OSCC [11]. We inferred that 
upregulation of YAP and ΔNp63 may play a role in 
human oral carcinogenesis. Furthermore, in analysis 
of YAP immunolabeling scores, score 3 was noted in 
2.0% (1/50) of low-grade OED, 54.0% (27/50) of 
high-grade OED, and 68.0% (34/50) of CIS. 
Additionally, the following percentages of ΔNp63- 
positive cells were observed: 24.8% in low-grade 
OED, 51.5% in high-grade OED, and 67.4% in CIS. 
These results showed that the number of score 3 cases 
and percentage of ΔNp63-positive cells in high-grade 
OED and CIS were higher than those in low-grade 
OED. The fourth edition of the World Health 
Organization Classification of Tumours of the Head 
and Neck described a highly significant difference in 
the risk of malignant progression between low- and 
high-grade dysplasia, and high-grade dysplasia and 
CIS are associated with a higher risk of invasion [16]. 
Lam-Himlin et al. [17] reported that YAP was 
significantly correlated with a malignant phenotype 
in the esophagus and stomach. Matsubara et al. [18] 
found that high ΔNp63 expression was involved 
in malignant transformation in oral OED. Taken 
together, the results of these studies and our 
findings support our inference that score 3, in 
combination with the percentage of 
ΔNp63-positive cells, might facilitate the 
identification of precancerous oral lesions and 
prognostic value.  
Both YAP immunolabeling scores and 
percentage of ΔNp63- positive cells in all samples 
were high in OSCC. In previous study, ΔNp63 
was shown to not only directly bind to the region 
of YAP promoter and induce its expression but 
also enhance YAP activity in SCC cell lines[14]. 
However, Ehsanian R et al show that ΔNp63 
inhibits YAP expression, binds the YAP 
promoter, and suppresses cell death in SCC cell 
lines[19]. Our findings are consistent with the 
former study. Our study conducted on human 
tissue specimens and it might be strongly suggest 
the actual role of YAP and ΔNp63 in tumor tissue. 
Therefore, in vitro studies that reproduce the 
environment similar to the tumor tissue will be 
necessary to evaluate interactions of YAP and 
ΔNp63 in OSCC. 
 Strong YAP expression was observed in the 
cell cytoplasm (type C) or nuclei (type N) in 
high-grade OED and CIS. YAP plays different 
 
 
Figure 2. YAP immunolabeling scores (A) and percentage of ΔNp63-positive cells (B) in oral 
samples. YAP and ΔNp63 expression in low-grade OED was significantly lower than that in 
high-grade OED and CIS (P<0.05). There was no significant difference in YAP and ΔNp63 
expression between in high-grade OED and CIS (P>0.05). YAP immunolabeling scores in oral 
samples (C). Normal: normal oral mucosa, hyperplasia: epithelial hyperplasia, dys (low): 
low-grade OED, dys (high): high-grade OED, CIS: carcinoma in situ. The numbers of score 3 
cases in high-grade OED and CIS were higher than those in normal oral mucosa, epithelial 
hyperplasia and low-grade OED. n.s.: not significant, *P<0.05, **P<0.01. 
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roles in the cytoplasm and nucleus. Furthermore, 
elevated nuclear YAP promotes proliferation, inhibits 
differentiation, and maintains an undifferentiated 
state both in vivo and in vitro in skin [17]. YAP 
cytoplasmic localization is crucial for differentiation 
of epithelial progenitors of adult airways [18]. Thus, it 
was suggested that type C is the differentiated state 
and type N is the undifferentiated state. In this study, 
YAP expression in high-grade OED and CIS was 
mainly distributed in the cell cytoplasm (type C). In 
contrast, Xiao et al. [15] found that precancerous 
cervical lesions and SCC groups, YAP labeling was 
predominately noted in nuclei of cells residing in 
squamous epithelium.  
 
 
Figure 3. Representative photomicrographs of hematoxylin-eosin (H&E) staining (A, D, G, J, and M) and immunohistochemical staining for YAP (B, E, H, K, and N) and ΔNp63 
(C, F, I, L, and O) in OSCC. OSCC cases were categorized as well- (A–C), moderately (D–I), and poorly (J–O) differentiated. In well-differentiated OSCC, YAP and ΔNp63 
expression was found at tumor borders; YAP and ΔNp63 were observed in cell nuclei (A–C). Moderately differentiated OSCC displayed two patterns that tended to have 
maturation or less maturation (D and G). In the former, YAP and ΔNp63 expression levels were similar to those in well-differentiated OSCC (D–F). In the latter, YAP and ΔNp63 
expression patterns were similar to those in poorly differentiated OSCC (G–I). In poorly differentiated OSCC, YAP and ΔNp63 were expressed in nearly all malignant epithelial 
cells; YAP was strongly observed in cell cytoplasm or nuclei, while ΔNp63 was seen in cell nuclei (J–O). Bars: 20 μm. 
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Figure 4. YAP immunolabeling scores (A) and percentage of ΔNp63-positive cells 
(B) in OSCC. OSCC: oral squamous cell carcinoma, OSCC (well): well-differentiated 
oral squamous cell carcinoma, OSCC (moderate): moderately differentiated oral 
squamous cell carcinoma, OSCC (poor): poorly differentiated oral squamous cell 
carcinoma. Both YAP immunolabeling scores and percentage of ΔNp63-positive cells 
in all samples were high, and there was no significant difference in YAP expression 
among the three groups (P>0.05). YAP immunolabeling scores in OSCC (C). OSCC 
(well): well-differentiated oral squamous cell carcinoma, OSCC (moderate): 
moderately differentiated oral squamous cell carcinoma, OSCC (poor): poorly 
differentiated oral squamous cell carcinoma. The numbers of score 3 cases in 
moderately and poorly differentiated OSCC were higher than that in 
well-differentiated OSCC. n.s.: not significant, *P<0.05, **P<0.01. 
 
Human papillomavirus (HPV) plays a pivotal 
role in the pathogenesis of cervical cancer. However, 
tobacco and alcohol are the two most important 
known risk factors for the development of oral cancer, 
while HPV infection is considered a cofactor. 
Furthermore, in neoplastic lesions such as CIS, 
histologically features of oral mucosa differ from 
those of the cervix. CIS in oral mucosa is marked by 
atypical cells in the basal and parabasal layers while 
maintaining the maturation and differentiation of 
stratified squamous epithelium. Conversely, CIS in 
the cervix displays full-thickness atypia of the 
epithelium. Thus, the mechanism of cancerization and 
differentiation of the epithelium differ in oral mucosa 
versus the cervix and explain the differences in YAP 
expression between these sites. In OSCC, strong YAP 
expression was predominantly distributed in the cell 
cytoplasm (type C). Multiple groups reported that 
YAP nuclear localization was associated with 
development and progression of invasive cancer 
[3,6-9]. However, in a previous report [17], in primary 
or metastatic gastric adenocarcinoma and adenocarc-
inoma of the esophagus, there was a consistent 
finding of YAP nuclear and cytoplasmic localization. 
We suggest that an overabundance of YAP results 
from gene amplification or increased transcription, 
subsequently causing YAP nuclear or cytoplasmic 
expression in dysplastic and malignant cells. 
In previous studies, YAP overexpression was an 
independent predictor of prognosis and might 
account for higher proliferation, metastasis, and poor 
survival outcome [20-25]. In the present study, the 
survival rate of OSCC tended to be lower in the YAP 
high expression group (score 3) than in the YAP low 
expression group (scores 0–2), and the disease-free 
survival rate was significantly lower in the score 3 
group than in the score 1 group. Furthermore, the 
numbers of score 3 cases in moderately and poorly 
differentiated OSCC were higher than that in 
well-differentiated OSCC. Taken together, YAP 
expression, especially score 3, might contribute to 
accurate prediction of prognosis for patients 
following surgery. 
 
 
Figure 5. Kaplan-Meier analysis of disease-free survival and overall survival rate of 
OSCC patients relative to YAP expression. OSCC patients were classified into two 
groups: YAP high expression group and YAP low expression group (A, B); score 3 
group and score 1 group (C, D); or score 3 group and score 2 group (E, F). The YAP 
high expression group tended to have lower survival rates than the YAP low 
expression group (A, B), and the disease-free survival rate in the score 3 group was 
significantly lower than that in the score 1 group (P<0.05) (C). 
 
In conclusion, varying YAP levels were observed 
in normal oral mucosa, epithelial hyperplasia, oral 
OED (low/high grade), CIS, and OSCC tissues. YAP 
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and ΔNp63 expression was correlated with grade of 
oral OED, and YAP expression was associated with 
OSCC survival rate. Thus, YAP and ΔNp63 
expression may serve as markers to distinguish 
development and progression of OSCC. 
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